1
|
Ando H, Shimizu-Okabe C, Okura N, Yafuso T, Kosaka Y, Kobayashi S, Okabe A, Takayama C. Reduced gene expression of KCC2 accelerates axonal regeneration and reduces motor dysfunctions after tibial nerve severance and suturing. Neuroscience 2024:S0306-4522(24)00212-4. [PMID: 38788828 DOI: 10.1016/j.neuroscience.2024.05.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 04/09/2024] [Accepted: 05/15/2024] [Indexed: 05/26/2024]
Abstract
Gamma-aminobutyric acid and glycine (GABA/Gly) are predominantly inhibitory neurotransmitters in the mature central nervous system; however, they mediate membrane potential depolarization during development. These differences in actions depend on intracellular Cl- concentrations ([Cl-]i), which are primarily regulated by potassium chloride cotransporter 2 (KCC2). After nerve injury, KCC2 expression markedly decreases and GABA/Gly mediate depolarization. Following nerve regeneration, KCC2 expression recovers and GABA/Gly become inhibitory, suggesting that KCC2 reduction and GABA/Gly excitation may be crucial for axonal regeneration. To directly clarify their involvement in regeneration, we analyzed recovery processes after tibial nerve severance and suturing between heterozygous KCC2 knockout mice (HT), whose KCC2 levels are halved, and their wild-type littermates (WT). Compared with WT mice, the sciatic functional index-indicating lower limb motor function-was significantly higher until 28 days after operation (D28) in HT mice. Furthermore, at D7, many neurofilament-positive fibers were elongated into the distal part of the ligated nerve in HT mice only, and myelinated axonal density was significantly higher at D21 and D28 in HT animals. Electron microscopy and galanin immunohistochemistry indicated a shorter nerve degeneration period in HT mice. Moreover, a less severe decrease in choline acetyltransferase was observed in HT mice. These results suggest that nerve degeneration and regeneration proceed more rapidly in HT mice, resulting in milder motor dysfunction. Via similar microglial activation, nerve surgery may reduce KCC2 levels more rapidly in HT mice, followed by earlier increased [Cl-]i and longer-lasting GABA/Gly excitation. Taken together, reduced KCC2 may accelerate nerve regeneration via GABA/Gly excitation.
Collapse
Affiliation(s)
- Hironobu Ando
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Chigusa Shimizu-Okabe
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Nobuhiko Okura
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Tsukasa Yafuso
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Yoshinori Kosaka
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Shiori Kobayashi
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Akihito Okabe
- Department of Nutritional Science, Faculty of Health and Welfare, Seinan Jo Gakuin University, Fukuoka 803-0835, Japan
| | - Chitoshi Takayama
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan.
| |
Collapse
|
2
|
Carvajal LA, Robinson B, Kosaka Y, Jacob T, Lee J, Hood T, Baker K, Kaempf A, Amara SNA, Pucilowska J, Lind E, Tognon C, Tyner J, Kumar P, Vu T, DiMartino J. P392: PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000844456.64162.e9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Yafuso T, Kosaka Y, Shimizu-Okabe C, Okura N, Kobayashi S, Kim J, Matsuda K, Kinjo D, Okabe A, Takayama C. Slow progression of sciatic nerve degeneration and regeneration after loose ligation through microglial activation and decreased KCC2 levels in the mouse spinal cord ventral horn. Neurosci Res 2022; 177:52-63. [PMID: 34757085 DOI: 10.1016/j.neures.2021.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/17/2021] [Accepted: 10/25/2021] [Indexed: 10/20/2022]
Abstract
Peripheral nerve injury affects motor functions. To reveal the mechanisms underlying motor dysfunction and recovery after nerve compression, which have not been precisely examined, we investigated the temporal relationship among changes in motor function, nerve histopathology, and marker molecule expression in the spinal cord after loose ligation of the mouse sciatic nerve. After ligation, sciatic motor function suddenly declined, and axons gradually degenerated. During degeneration, galanin was localized in motor neuron cell bodies. Then, in the ventral horn, microglia were activated, and expression of choline acetyltransferase (ChAT), a synthetic enzyme of acetylcholine, and potassium chloride co-transporter 2 (KCC2), which shifts the action of γ-amino butyric acid (GABA) and glycine to inhibitory, decreased. Motor function recovery was insufficient although axonal regeneration was complete. ChAT levels gradually recovered during axonal regeneration. When regeneration was nearly complete, microglial activation declined, and KCC2 expression started to increase. The KCC2 level sufficiently recovered when axonal regeneration was complete, suggesting that the excitatory action of GABA/glycine may participate in axonal regeneration. Furthermore, these changes proceeded slower than those after severance, suggesting that loose ligation, compression, may mediate slower progression of degeneration and regeneration than severance, and these changes may cause the motor dysfunction and its recovery.
Collapse
Affiliation(s)
- Tsukasa Yafuso
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Yoshinori Kosaka
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Chigusa Shimizu-Okabe
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Nobuhiko Okura
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Shiori Kobayashi
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Jeongtae Kim
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan; Department of Anatomy, Kosin University College of Medicine, Busan, 49267, Republic of Korea
| | - Koyata Matsuda
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Daichi Kinjo
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan
| | - Akihito Okabe
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan; Department of Nutritional Science, Faculty of Health and Welfare, Seinan Jo Gakuin University, Fukuoka, 803-0835, Japan
| | - Chitoshi Takayama
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa, 9030215, Japan.
| |
Collapse
|
4
|
Shimizu-Okabe C, Kobayashi S, Kim J, Kosaka Y, Sunagawa M, Okabe A, Takayama C. Developmental Formation of the GABAergic and Glycinergic Networks in the Mouse Spinal Cord. Int J Mol Sci 2022; 23:ijms23020834. [PMID: 35055019 PMCID: PMC8776010 DOI: 10.3390/ijms23020834] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 01/07/2022] [Accepted: 01/11/2022] [Indexed: 12/15/2022] Open
Abstract
Gamma-aminobutyric acid (GABA) and glycine act as inhibitory neurotransmitters. Three types of inhibitory neurons and terminals, GABAergic, GABA/glycine coreleasing, and glycinergic, are orchestrated in the spinal cord neural circuits and play critical roles in regulating pain, locomotive movement, and respiratory rhythms. In this study, we first describe GABAergic and glycinergic transmission and inhibitory networks, consisting of three types of terminals in the mature mouse spinal cord. Second, we describe the developmental formation of GABAergic and glycinergic networks, with a specific focus on the differentiation of neurons, formation of synapses, maturation of removal systems, and changes in their action. GABAergic and glycinergic neurons are derived from the same domains of the ventricular zone. Initially, GABAergic neurons are differentiated, and their axons form synapses. Some of these neurons remain GABAergic in lamina I and II. Many GABAergic neurons convert to a coreleasing state. The coreleasing neurons and terminals remain in the dorsal horn, whereas many ultimately become glycinergic in the ventral horn. During the development of terminals and the transformation from radial glia to astrocytes, GABA and glycine receptor subunit compositions markedly change, removal systems mature, and GABAergic and glycinergic action shifts from excitatory to inhibitory.
Collapse
Affiliation(s)
- Chigusa Shimizu-Okabe
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara 903-0215, Japan; (C.S.-O.); (S.K.); (Y.K.); (M.S.)
| | - Shiori Kobayashi
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara 903-0215, Japan; (C.S.-O.); (S.K.); (Y.K.); (M.S.)
| | - Jeongtae Kim
- Department of Anatomy, Kosin University College of Medicine, Busan 49267, Korea;
| | - Yoshinori Kosaka
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara 903-0215, Japan; (C.S.-O.); (S.K.); (Y.K.); (M.S.)
| | - Masanobu Sunagawa
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara 903-0215, Japan; (C.S.-O.); (S.K.); (Y.K.); (M.S.)
| | - Akihito Okabe
- Department of Nutritional Science, Faculty of Health and Welfare, Seinan Jo Gakuin University, Fukuoka 803-0835, Japan;
| | - Chitoshi Takayama
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara 903-0215, Japan; (C.S.-O.); (S.K.); (Y.K.); (M.S.)
- Correspondence: ; Tel.: +81-98-895-1103 or +81-895-1405
| |
Collapse
|
5
|
Kosaka Y, Yafuso T, Shimizu-Okabe C, Kim J, Kobayashi S, Okura N, Ando H, Okabe A, Takayama C. Development and persistence of neuropathic pain through microglial activation and KCC2 decreasing after mouse tibial nerve injury. Brain Res 2020; 1733:146718. [PMID: 32045595 DOI: 10.1016/j.brainres.2020.146718] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 01/27/2020] [Accepted: 02/07/2020] [Indexed: 12/20/2022]
Abstract
Gamma-amino butyric acid (GABA) is an inhibitory neurotransmitter in the mature brain, but is excitatory during development and after motor nerve injury. This difference in GABAergic action depends on the intracellular chloride ion concentration ([Cl-]i), primarily regulated by potassium chloride co-transporter 2 (KCC2). To reveal precise processes of the neuropathic pain through changes in GABAergic action, we prepared tibial nerve ligation and severance models using male mice, and examined temporal relationships amongst changes in (1) the mechanical withdrawal threshold in the sural nerve area, (2) localization of the molecules involved in GABAergic transmission and its upstream signaling in the dorsal horn, and (3) histology of the tibial nerve. In the ligation model, tibial nerve degeneration disappeared by day 56, but mechanical allodynia, reduced KCC2 localization, and increased microglia density remained until day 90. Microglia density was higher in the tibial zone than the sural zone before day 21, but this result was inverted after day 28. In contrast, in the severance model, all above changes were detected until day 28, but were simultaneously and significantly recovered by day 90. These results suggested that in male mice, allodynia may be caused by reduced GABAergic synaptic inhibition, resulting from elevated [Cl-]i after the reduction of KCC2 by activated microglia. Furthermore, our results suggested that factors from degenerating nerve terminals may diffuse into the sural zone, whereby they induced the development of allodynia in the sural nerve area, while other factors in the sural zone may mediate persistent allodynia through the same pathway.
Collapse
Affiliation(s)
- Yoshinori Kosaka
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan
| | - Tsukasa Yafuso
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan
| | - Chigusa Shimizu-Okabe
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan
| | - Jeongtae Kim
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan; Department of Veterinary Anatomy, College of Veterinary Medicine, Jeju National University, Jeju 63243, Republic of Korea
| | - Shiori Kobayashi
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan
| | - Nobuhiko Okura
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan
| | - Hironobu Ando
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan
| | - Akihito Okabe
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan; Department of Nutritional Science, Faculty of Health and Welfare, Seinan Jo Gakuin University, Fukuoka 803-0835, Japan
| | - Chitoshi Takayama
- Department of Molecular Anatomy, Graduate School of Medicine, University of the Ryukyus, 207 Uehara 207, Nishihara, Okinawa 9030215, Japan.
| |
Collapse
|
6
|
Ogura K, Imagumbai T, Kosaka Y, Hattori T, Hiraoka S, Ogata T, Kokubo M. Outcomes of Radiotherapy for Brain Metastases Patients without Active Extracranial Disease. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Ogata T, Kosaka Y, Imagumbai T, Ogura K, Hattori T, Hiraoka S, Kokubo M. Outcome of Stereotactic Body Radiotherapy for Patients with Histologically Proven Stage I Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Abstract OT1-05-04: Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy ( JONIE4:J-CAT trial). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-05-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It is well known that the prognosis of non pCR TNBC patients was poor after anthracycline and taxan treatment. For such patients, capecitabine seems to be effective to reduce recurrence based on the HR 0.58 of the CREATE X trial (Masuda, N. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 376, 2147. 2017) . However, the target of capecitabine is still unclear for TNBC. We classified non pCR tumors as BRCAness and Sporadic using BRCAness test(MRC-Holland, Amsterdam, the Netherlands). The recurrence rate of the BRCAness group was about 70%. Carboplatine is expected to be effective against BRCAness tumors, as it is a DNA damaging agent. In this study BRCAness can be checked just before carboplatin treatment using surgical specimens. Then the efficacy of carboplatin will be directly known to make comparison between DFS in the carboplatin group and that of the observation group.
Trial design: This is anopen label, randomized phase III study that will enroll TNBC with residual invasive cancer after surgery with preoperative chemotherapy including both anthracycrine and taxan. Patients are randomly assigned to either the carboplatin group or observation group. The patients in the carboplatin group are treated with carboplatin at AUC 6 and those in the observation group are observed at only 3 years.
Eligibility criteria:
1) ER and PgR<1%, HER2 0, 1+ or 2+ with FISH negative on core needle biopsy before the chemotherapy and surgical specimens.
2) Preoperative chemotherapy including both anthracycrine and taxan.
3) Residual invasive cancer on breast tumors or lymph node metastasis in surgical specimens.
4) 20-79 year old women.
5) No chemotherapy within 5 years.
6) Not bilateral breast cancer, without metastasis, no prior breast cancer.
7) No severe bone marrow suppression.
Specific aims:Primary objective is DFS (Disease Free Survival). Secondary objectives are overall survival and safety.
STATISTICAL METHODS:
The 3 years recurrence rate of the observation group was estimated as 40% and hazard ratio at 0.58 based on the CREATE X trial. For both groups, 135 patients are necessary. This study is powered to approximately 80% to test the superiority of carboplatin group at a 2-sided α=0.05 using a stratified log-rank test.
Activation Date:22ndMarch 2018. No patients had been enrolled till 3rd July.
Citation Format: Tanino H, Suzuki M, Kaise H, Miyashita M, Chishima T, Hayashi M, Miyoshi Y, Futamura M, Ohtani S, Nagahashi M, Ohta T, Kosaka Y, Ishikawa T, Hasegawa Y, Kubota T, Sangai T, Iwatani T, Yamada A, Akazawa K, Kohno N. Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4:J-CAT trial) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-05-04.
Collapse
Affiliation(s)
- H Tanino
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Suzuki
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - H Kaise
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Miyashita
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Chishima
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Hayashi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Miyoshi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Futamura
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - S Ohtani
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - M Nagahashi
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Ohta
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Kosaka
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Ishikawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - Y Hasegawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Kubota
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Sangai
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - T Iwatani
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - A Yamada
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - K Akazawa
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| | - N Kohno
- Kobe University, Kobe, Hyogo, Japan; National Hospital Organization Chiba Medical Center, Chiba City, Chiba, Japan; Tokyo Medical University Ibaraki Medical Center, Inashikigun, Ibaraki, Japan; Kohnan Hospital, Kobe, Hyogo, Japan; Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan; Dokkyo Medical University, Mibu, Tochigi, Japan; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Gifu University, Gifu, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Niigata University, Niigata, Japan; St. Marianna University School of Medicine, Kawasaki, Knagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Tokyo Medical University, Shinjuku-ku, Tokyo, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Kobe Kaisei Hospital, Kobe, Hyogo, Japan; Chiba University Graduate School of Medicine, Chiba, Chiba, Japan; Chigasaki Municipal Hospital, Chigasaki, Kanagawa, Japan; Kamiiida Daiichi General Hospital, Nagoya City, Aichi, Japan
| |
Collapse
|
9
|
Ohtani S, Yasuaki S, Takada M, Ohi Y, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Effectiveness of Neo-Adjuvant Systemic Therapy for Basal HER2 type Breast Cancer – Results from Retrospective Cohort Study of Japan Breast Cancer Research Group (JBCRG) – C03. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30506-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
10
|
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai WC, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd8-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Dysregulation of the estrogen receptor gene (ESR1) is an established mechanism of inducing endocrine therapy resistance. We previously discovered a chromosomal translocation event generating an estrogen receptor gene fused in-frame to C-terminal sequences of YAP1 (ESR1-YAP1) that contributed to endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer models. This study compares functional, transcriptional, and pharmacological properties of additional ESR1 gene fusion events of both early stage (ESR1-NOP2) late stage (ESR1-YAP1 and ESR1-PCDH11x) breast cancers to gain a better understanding of therapeutic resistance and metastasis. Understanding the role of ESR1 fusions in inducing metastasis is critical, since the primary cause of death in breast cancer patients is through metastasis to distant sites.
Methods. RNA-seq screens identified ESR1 fusions from early and late stage, endocrine therapy resistant breast tumor samples. Functional experiments were conducted using ER+ breast cancer cell lines, xenograft, and PDX models to test the ability of ESR1 fusions to induce therapeutic resistance and metastasis. ChIP-seq and RNA-seq were performed to examine transcriptional properties and differential gene expression induced by the fusions which directed subsequent pharmacological experiments with a CDK4/6 inhibitor.
Results. ESR1-YAP1 and ESR1-PCDH11x promoted estrogen-independent and fulvestrant-resistant growth in vitro and induced greater tumor growth and increased metastatic capacity to the lungs of xenografted mice. In contrast, the ESR1-NOP2 fusion was sensitive to low estrogen conditions in vitro, and did not promote tumor growth. RNA-seq profiling revealed E2F targets pathway as the most highly enriched pathway induced by the ESR1 fusions. IHC revealed higher levels of pRb in ESR1-YAP1 and ESR1-PCDH11x xenograft tumors and subsequent CDK4/6 inhibition completely blocked tumor growth in an ESR1-YAP1 PDX model. Integrating RNA-seq with ChIP-seq data, we discovered a set of EMT and metastasis genes bound by all ESR1 fusions and WT-ER, but whose expression was strongly and uniquely up-regulated only by the ESR1-YAP1 and ESR1-PCDH11x fusions. These studies also revealed gained sites bound only by the ESR1-YAP1 and ESR1-PCDH11x fusions, not bound by WT-ER nor ESR1-NOP2. Genes mapping to these sites have a role in metastatic biology and were highly up-regulated by the YAP1 and PCDH11x fusions, potentially mediated by long range transcriptional activation.
Conclusion. ESR1-YAP1 and ESR1-PCDH11x are driver fusions that occur in drug-resistant, advanced stage breast cancer and are a new class of recurrent somatic mutation that can cause acquired endocrine therapy resistance, yet can be treated with CDK4/6 inhibition. These driver fusions also confer increased metastatic ability through their ability to drive expression of genes that contribute to EMT and metastasis. In contrast, ESR1-NOP2 did not produce functional protein and appears to be a passenger event. These studies may provide pre-clinical rationale for targeting ESR1 translocated breast tumors, since the presence of an ESR1 driver fusion places a patient in a therapeutic category where none of the currently available endocrine therapies are likely to be effective.
Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD8-03.
Collapse
Affiliation(s)
- JT Lei
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Shao
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Zhang
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Iglesia
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - DW Chan
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Cao
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Anurag
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - P Singh
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - SM Kavuri
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Matsunuma
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Schmidt
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - Y Kosaka
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Crowder
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - J Hoog
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Phommaly
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - R Goncalves
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Ramalho
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - RM Rodrigues-Peres
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - W-C Lai
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - O Hampton
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - A Rogers
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - E Tobias
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - P Parikh
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - S Davies
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - V Suman
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - K Hunt
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - M Watson
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - KA Hoadley
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - CM Perou
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - CJ Creighton
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - C Maher
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; Washington University, St. Louis, MO; University of North Carolina; Kitasato University School of Medicine, Japan; University of Sao Paulo School of Medicine, Brazil; State University of Campinas, Brazil; Mayo Clinic; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
11
|
Akamatsu H, Nakamura K, Ebara T, Inaba K, Itasaka S, Jingu K, Kosaka Y, Murai T, Nagata K, Soejima T, Takahashi S, Toyoda T, Toyoshima S, Nemoto K, Akimoto T. EP-1366: Radiotherapy aimed at functional preservation in patients with small cell carcinoma of the bladder. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31801-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Yamauchi Y, Kimura Y, Kosaka Y, Nobuta Y, Hino T, Nishimura K, Ueda Y. Hydrogen Isotope Retention and Desorption in Tungsten during Glow Discharges. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a12710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Yamauchi
- Laboratory of Plasma Physics and Engineering, Hokkaido University, Sapporo, Hokkaido, 060-8628, Japan
| | - Y. Kimura
- Laboratory of Plasma Physics and Engineering, Hokkaido University, Sapporo, Hokkaido, 060-8628, Japan
| | - Y. Kosaka
- Laboratory of Plasma Physics and Engineering, Hokkaido University, Sapporo, Hokkaido, 060-8628, Japan
| | - Y. Nobuta
- Laboratory of Plasma Physics and Engineering, Hokkaido University, Sapporo, Hokkaido, 060-8628, Japan
| | - T. Hino
- Laboratory of Plasma Physics and Engineering, Hokkaido University, Sapporo, Hokkaido, 060-8628, Japan
| | - K. Nishimura
- National Institute for Fusion Science, Toki, Gifu, 509-5292, Japan
| | - Y. Ueda
- Graduate School of Engineering, Osaka University, Suita, Osaka, 565-0871, Japan
| |
Collapse
|
13
|
Lei JT, Shao J, Zhang J, Iglesia M, Cao J, Chan DW, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Lai WC, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Chen X, Perou CM, Creighton CJ, Maher C, Ellis MJ. Abstract PD2-03: Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd2-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. We previously reported an alternative ESR1 somatic gain-of-function chromosomal translocation event in a patient presenting with aggressive, endocrine therapy resistant estrogen receptor (ER) positive disease, producing an in-frame fusion gene consisting of N-terminal ESR1 and the C-terminus of the Hippo pathway coactivator YAP1 (ESR1-YAP1). We recently identified another ESR1 fusion through RNA sequencing (RNA-seq) in advanced stage ER+ disease from a chest wall recurrence in a male patient that was refractory to multiple lines of treatment. Two examples of fusions discovered in primary breast cancer samples include ESR1 fused in-frame to C-terminal sequences from NOP2 (ESR1-NOP2), identified in a resistant cohort from a RNA-seq screen focused on 81 primary breast cancers from aromatase inhibitor clinical trials, and a second ESR1 fusion, fused in-frame to the entire coding sequence of POLH (ESR1-POLH), that was identified from RNA-seq analysis of 728 Cancer Genome Atlas breast samples. This current study extends our previous characterization of ESR1-YAP1 by comparing functional and pharmacological properties of these three additional ESR1 gene fusion events of both early stage and advanced breast cancers.
Methods. In vitro and in vivo experiments were conducted to test ESR1 fusions to induce therapeutic resistance, and metastasis. The transcriptional and binding properties of each fusion was also examined. Pharmacological inhibition with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, was utilized to assess drug sensitivity in ESR1 fusion containing breast cancer cells and in a patient derived xenograft (PDX) model expressing ESR1-YAP1 (WHIM18).
Results. The YAP1 and PCDH11x fusions conferred estrogen-independent and fulvestrant-resistant growth. Immunohistochemistry revealed significantly higher numbers of ER+ cells in lungs of mice xenografted with T47D cells expressing the YAP1 and PCDH11x fusions compared to YFP control, NOP2 and POLH fusions. Results from ChIP-seq and microarray studies suggest that these two fusions promote proliferation and metastasis through genomic action by binding estrogen response elements (ERE) and subsequent gene activation. We thereby define these fusions as “canonical” fusions compared to “non-canonical” NOP2 and POLH fusions, which demonstrated dramatically decreased genomic binding ability. The non-canonical fusions induced genes associated with basal-like breast cancer and promoted HER2, EGFR, and MAPK gene expression signatures in contrast to genes associated with cell cycle/proliferation induced by canonical fusions. The proliferative ability of canonical fusion-containing ER+ cells was inhibited by Palbociclib in a dose-dependent manner. In vivo WHIM18 tumors in mice fed with Palbociclib-containing chow demonstrated significantly reduced tumor volume, growth rate, and weight compared to tumors in mice on control chow.
Conclusions. In-frame ERE activating canonical fusions occur in end-stage drug resistant advanced breast cancer and can be added to ESR1 point mutations as a class of recurrent somatic mutation that may cause acquired resistance. Growth induced by these fusions can be antagonized by Palbociclib and is potentially clinically helpful.
Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Cao J, Chan DW, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Chen X, Perou CM, Creighton CJ, Maher C, Ellis MJ. Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD2-03.
Collapse
Affiliation(s)
- JT Lei
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Shao
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Zhang
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - M Iglesia
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Cao
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - DW Chan
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - X He
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - Y Kosaka
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Schmidt
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Matsunuma
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Haricharan
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Crowder
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - J Hoog
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Phommaly
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - R Goncalves
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Ramalho
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - W-C Lai
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - O Hampton
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - A Rogers
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - E Tobias
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - P Parikh
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - S Davies
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Ma
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - V Suman
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - K Hunt
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - M Watson
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - KA Hoadley
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - A Thompson
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - X Chen
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - CM Perou
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - CJ Creighton
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - C Maher
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| | - MJ Ellis
- Baylor College of Medicine, Houston, TX; Washington University School of Medicine, St. Louis, MO; University of North Carolina, Chapel Hill, NC; Kitasato University School of Medicine, Minato, Japan; University of Sao Paulo School of Medicine, Sao Paulo, Brazil; State University of Campinas, Sao Paulo, Brazil; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
14
|
Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Abstract P5-16-04: A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: This study aimed to evaluate response to neoadjuvant chemotherapy (NAC) for patients with hormone receptor-negative (HR-negative) breast cancer (BC) to identify subtypes that require anthracycline treatment.
Methods: In total, 103 patients with operable HR-negative BC were registered. They were randomely assigned to administration of 6 cycles of docetaxel (75mg/m2) and cyclophosphamide (600 mg/m2) (TC6) or 3 cycles of 5-fluorouracil (500 mg/m2), epirubicin (100mg/m2), and cyclophosphamide (500mg/m2) followed by 3 cycles of docetaxel (100mg/m2) (FEC-D). Cytokeratin (CK) 5/6 and EGFR expression were used to identify basal and non-basal triple-negative (TN) BC. The primary endpoint was pathological complete response (pCR); secondary endpoints were safety, breast-conserving surgery, disease-free survival, and overall survival. Predictive factors of pCR for each regimen were also evaluated.
Results:
The pCR rate was 36% for FEC-D and 25.5% for TC6, which did not differ significantly (P=0.265). When TN BC was subdivided into basal and non-basal subtypes, the pCR rate in the basal subtype was significantly lower for TC6 (13.6%) than for FEC-D (42.9%) (P=0.033), but did not significantly differ in the non-basal (TC6, 36.4%; FEC-D, 25.0%) and HER2-positive (TC6, 41.7%; FEC-D, 35.7%) cases.
The relative dose intensities of epirubicin and docetaxel in FEC-D and docetaxel in TC6 were 96.3±13.0%, 93.5±14.6%, and 93.9±16.3% (mean±SD), respectively. Occurrence of grade ≥2 adverse events was significant in FEC-D-treated patients. Poor appetite (P<0.001), nausea (P<0.001), vomiting (P<0.001), dysgeusia (P=0.03), and fatigue (P=0.05) were significantly more common for FEC-D than TC6. Patients treated with FEC-D experienced significantly more febrile neutropenia and anemia (P=0.016 and 0.017, respectively).
The rates of breast-conserving surgery were 68.0 and 72.3% for FEC-D and TC6, respectively (P=0.641).
Patients achieved pCR had better DFS (log rank test, P = 0.287) and OS (log rank test, P = 0.069), though not significant. Patients treated with FEC-D had better DFS (log rank test, P = 0.107) and OS (log rank test, P = 0.159), though not significant. Among patients with TN BC, those treated with FEC-D had significantly better DFS (log rank test, P = 0.016) and OS (log rank test, P = 0.034) than treated with TC6.
Low ALDH1 expression and high topo IIα protein expression were strongly correlated with pCR in FEC-D, with odds ratios (ORs) of 4.33 [95% CI, 1.02–18.38] and 4.08 [0.97–17.2], respectively. ALDH1 was also associated with pCR in TC, OR=3.50 [0.84–14.6]. Other factors, including age, tumor size, nodal status, tumor grade, Ki67, p53, and TOP 2A status were not associated with pCR in either regimen.
Conclusions:We found that TC6 was less effective than FEC-D for treating HR-negative BC because it was insufficient for TNBC, particularly for basal BC. This suggests that anthracycline is more important than taxane for basal BC. Additionally, ALDH1 could be a marker for resistance to conventional chemotherapy.
Citation Format: Narui K, Ishikawa T, Shimizu D, Tanabe M, Sasaki T, Oba MS, Morita S, Nawata S, Kida K, Mogaki M, Doi T, Tsugawa K, Ogata H, Ota T, Kosaka Y, Sengoku N, Kuranami M, Saito Y, Suzuki Y, Suto A, Arioka H, Chishima T, Ichikawa Y, Endo I, Tokuda Y. A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-04.
Collapse
Affiliation(s)
- K Narui
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ishikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - D Shimizu
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Tanabe
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Sasaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - MS Oba
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Morita
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - S Nawata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Kida
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Mogaki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Doi
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - K Tsugawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Ogata
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Ota
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Kosaka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - N Sengoku
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - M Kuranami
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Saito
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Suzuki
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - A Suto
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - H Arioka
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - T Chishima
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Ichikawa
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - I Endo
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| | - Y Tokuda
- Yokohama City University Medical Center, Yokohama, Japan; Tokyo Medical Univercity, Tokyo, Japan; Yokosuka Kyosai Hospital, Yokosuka, Japan; Shonan Kinen Hospital, Kamakura, Japan; St. Marianna Univercity School of Medicine, Kawasaki, Japan; Kitasato University, Sagamihara, Japan; Tokai University, Isehara, Japan; Yokohama Rosai Hospital, Yokohama, Japan; Yokohama City University, Yokohama, Japan
| |
Collapse
|
15
|
Kikawa Y, Kato H, Kosaka Y, Hashimoto K, Hohokabe E, Takebe S, Ueki K, Ogura K, Imagunbai T, Kokubo M. 96P Prevalence of hypothyroidism among breast cancer patients treated with radiation to the supraclavicular field: A single center survey. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw575.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Ueki K, Takayama K, Iizuka Y, Kimino G, Imagumbai T, Suginoshita Y, Tei H, Kosaka Y, Inokuma T, Kokubo M. Correlation Between Dose-Volumetric Parameters and Late Liver Dysfunction After Dynamic Tumor-Tracking Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia 2016; 23:59-66. [DOI: 10.1111/hae.13050] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/16/2016] [Indexed: 11/27/2022]
Affiliation(s)
- Y. Shinkoda
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima Japan
| | - A. Shirahata
- Kitakyushu Yahata Higashi Hospital; Kitakyushu Fukuoka Japan
| | - K. Fukutake
- Department of Laboratory Medicine; Tokyo Medical University; Tokyo Japan
| | - J. Takamatsu
- Japanese Red Cross Tokai-Hokuriku Block Blood Center; Seto Aichi Japan
| | - M. Shima
- Department of Paediatrics; Nara Medical University; Kashihara Nara Japan
| | - H. Hanabusa
- Department of Haematology; Ogikubo Hospital; Tokyo Japan
| | - H. Mugishima
- Department of Paediatrics; Nihon University Itabashi Hospital; Tokyo Japan
| | - H. Takedani
- Department of Joint Surgery; Research Hospital of the Institute of Medical Science; the University of Tokyo; Tokyo Japan
| | - K. Kawasugi
- Department of Internal Medicine; Teikyo University Hospital; Tokyo Japan
| | - M. Taki
- Department of Paediatrics; St. Marianna University School of Medicine; Kawasaki Kanagawa Japan
| | - T. Matsushita
- Department of Transfusion Medicine; Nagoya University Hospital; Nagoya Aichi Japan
| | - A. Tawa
- Department of Paediatrics; National Hospital Organization Osaka National Hospital; Osaka Japan
| | - K. Nogami
- Department of Paediatrics; Nara Medical University; Kashihara Nara Japan
| | - S. Higasa
- Division of Haematology; Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Hyogo Japan
| | - Y. Kosaka
- Department of Haematology and Oncology; Kobe Children's Hospital; Kobe Hyogo Japan
| | - T. Fujii
- Division of Blood Transfusion; Hiroshima University Hospital; Hiroshima Japan
| | - M. Sakai
- Department of Paediatrics; University of Occupational and Environmental Health; Kitakyushu Fukuoka Japan
| | - M. Migita
- Department of Paediatrics; Kumamoto Red Cross Hospital; Kumamoto Japan
| | - M. Uchiba
- Department of Blood Transfusion and Cell Therapy; Kumamoto University Hospital; Kumamoto Japan
| | - K. Kawakami
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima Japan
| | - K. Sameshima
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima Japan
| | - Y. Ohashi
- Department of Biostatistics; School of Public Health; the University of Tokyo; Tokyo Japan
| | - H. Saito
- National Hospital Organization Nagoya Medical Center; Nagoya Aichi Japan
| |
Collapse
|
18
|
Hashimoto O, Yoshida M, Koma Y, Yanai T, Hasegawa D, Kosaka Y, Nishimura N, Yokozaki H. 169 Contribution of cancer-associated fibroblasts and M2-polarized macrophages to neuroblastoma development. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30066-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Arai M, Ito S, Kosaka Y, Toda M, Kuroiwa M, Okamoto H. 0597. The relation between intestinal intramucosal ph and stress hormones in pig hemorrhagic shock model. Intensive Care Med Exp 2014. [PMCID: PMC4798586 DOI: 10.1186/2197-425x-2-s1-p40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
20
|
Shintani T, Takayama K, Kokubo M, Imagumbai T, Kosaka Y, Ueki N, Kimino G, Katakami N. Stereotactic Body Radiation Therapy as a Part of Definitive Treatment for Synchronous Double Primary Lung Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Shofty B, Bokstein F, Ram Z, Ben-Sira L, Freedman S, Kesler A, Constantini S, Shofty B, Mauda-Havakuk M, Ben-Bashat D, Dvir R, Pratt LT, Weizman L, Joskowicz L, Tal M, Ravid L, Ben-Sira L, Constantini S, Dodgshun A, Maixner W, Sullivan M, Hansford J, Ma J, Wang B, Toledano H, Muhsinoglu O, Luckman J, Michowiz S, Goldenberg-Cohen N, Schroeder K, Rosenfeld A, Grant G, McLendon R, Cummings T, Becher O, Gururangan S, Aguilera D, Mazewski C, Janss A, Castellino RC, Schniederjan M, Hayes L, Brahma B, MacDonald T, Osugi Y, Kiyotani C, Sakamoto H, Yanagisawa T, Kanno M, Kamimura S, Kosaka Y, Hirado J, Takimoto T, Nakazawa A, Hara J, Hwang E, Mun A, Kilburn L, Chi S, Knipstein J, Oren M, Dvir R, Hardy K, Rood B, Packer R, Kandels D, Schmidt R, Geh M, Breitmoser-Greiner S, Gnekow AK, Bergthold G, Bandopadhayay P, Rich B, Chan J, Santagata S, Hoshida Y, Ramkissoon S, Ramkissoon L, Golub T, Tabak B, Ferrer-Luna R, Weng PY, Stiles C, Grill J, Kieran MW, Ligon KL, Beroukhim R, Fisher MJ, Levin MH, Armstrong GT, Broad JH, Zimmerman R, Bilaniuk LT, Feygin T, Liu GT, Gan HW, Phipps K, Spoudeas HA, Kohorst M, Warad D, Keating G, Childs S, Giannini C, Wetjen N, Rao; AN, Nakamura H, Makino K, Hide T, Kuroda JI, Shinojima N, Yano S, Kuratsu JI, Rush S, Madden J, Hemenway M, Foreman N, Sie M, den Dunnen WFA, Lourens HJ, Meeuwsen-de Boer TGJ, Scherpen FJG, Kampen KR, Hoving EW, de Bont ESJM, Gnekow AK, Kandels D, Walker DA, Perilongo G, Grill J, Stokland T, Sehested AM, van Schouten AYN, de Paoli A, de Salvo GL, Pache-Leschhorn S, Geh M, Schmidt R, Gnekow AK, Gass D, Rupani K, Tsankova N, Stark E, Anderson R, Feldstein N, Garvin J, Deel M, McLendon R, Becher O, Karajannis M, Wisoff J, Muh C, Schroeder K, Gururangan S, del Bufalo F, Carai A, Macchiaiolo M, Messina R, Cacchione A, Palmiero M, Cambiaso P, Mastronuzzi A, Anderson M, Leary S, Sun Y, Buhrlage S, Pilarz C, Alberta J, Stiles C, Gray N, Mason G, Packer R, Hwang E, Biassoni V, Schiavello E, Bergamaschi L, Chiaravalli S, Spreafico F, Massimino M, Krishnatry R, Kroupnik T, Zhukova N, Mistry M, Zhang C, Bartels U, Huang A, Adamski J, Dirks P, Laperriere N, Silber J, Hawkins C, Bouffet E, Tabori U, Riccardi R, Rizzo D, Chiaretti A, Piccardi M, Dickmann A, Lazzareschi I, Ruggiero A, Guglielmi G, Salerni A, Manni L, Colosimo C, Falsini B, Rosenfeld A, Etzl M, Miller J, Carpenteri D, Kaplan A, Sieow N, Hoe R, Tan AM, Chan MY, Soh SY, Orphanidou-Vlachou E, MacPherson L, English M, Auer D, Jaspan T, Arvanitis T, Grundy R, Peet A, Bandopadhayay P, Bergthold G, Sauer N, Green A, Malkin H, Dabscheck G, Marcus K, Ullrich N, Goumnerova L, Chi S, Beroukhim R, Kieran M, Manley P, Donson A, Kleinschmidt-DeMasters B, Aisner D, Bemis L, Birks D, Mulcahy-Levy J, Smith A, Handler M, Rush S, Foreman N, Davidson A, Figaji A, Pillay K, Kilborn T, Padayachy L, Hendricks M, van Eyssen A, Parkes J, Gass D, Dewire M, Chow L, Rose SR, Lawson S, Stevenson C, Jones B, Pai A, Sutton M, Pruitt D, Fouladi M, Hummel T, Cruz O, de Torres C, Sunol M, Morales A, Santiago C, Alamar M, Rebollo M, Mora J, Sauer N, Dodgshun A, Malkin H, Bergthold G, Manley P, Chi S, Ramkissoon S, MacGregor D, Beroukhim R, Kieran M, Sullivan M, Ligon K, Bandopadhayay P, Hansford J, Messina R, De Benedictis A, Carai A, Mastronuzzi A, Rebessi E, Palma P, Procaccini E, Marras CE, Aguilera D, Castellino RC, Janss A, Schniederjan M, McNall R, Kim S, MacDOnald T, Mazewski C, Zhukova N, Pole J, Mistry M, Fried I, Krishnatry R, Stucklin AG, Bartels U, Huang A, Laperriere N, Dirks P, Zelcer S, Sylva M, Johnston D, Scheinemann K, An J, Hawkins C, Nathan P, Greenberg M, Bouffet E, Malkin D, Tabori U, Kiehna E, Da Silva S, Margol A, Robison N, Finlay J, McComb JG, Krieger M, Wong K, Bluml S, Dhall G, Ayyanar K, Moriarty T, Moeller K, Farber D. LOW GRADE GLIOMAS. Neuro Oncol 2014; 16:i60-i70. [PMCID: PMC4046289 DOI: 10.1093/neuonc/nou073] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/13/2023] Open
|
22
|
Kannan V, Misra BK, Kapadia A, Bajpai R, Deshpande S, Almel S, Sankhe M, Desai K, Shaikh M, Anand V, Kannan A, Teo WY, Ross J, Bollo R, Seow WT, Tan AM, Kang SG, Kim DS, Li XN, Lau CC, Mohila CA, Adesina A, Su J, Ichimura K, Fukushima S, Matsushita Y, Tomiyama A, Niwa T, Suzuki T, Nakazato Y, Mukasa A, Kumabe T, Nagane M, Iuchi T, Mizoguchi M, Tamura K, Sugiyama K, Nakada M, Kanemura Y, Yokogami K, Matsutani M, Shibata T, Nishikawa R, Takami H, Fukushima S, Fukuoka K, Yanagisawa T, Nakamura T, Arita H, Narita Y, Shibui S, Nishikawa R, Ichimura K, Matsutani M, Sands S, Guerry W, Kretschmar C, Donahue B, Allen J, Matsutani M, Nishikawa R, Kumabe T, Sugiyama K, Nakamura H, Sawamura Y, Fujimaki T, Hattori E, Arakawa Y, Kawabata Y, Aoki T, Miyamoto S, Kagawa N, Hirayama R, Fujimoto Y, Chiba Y, Kinoshita M, Takano K, Eino D, Fukuya S, Nakanishi K, Yamamoto F, Hashii Y, Hashimoto N, Hara J, Yoshimine T, Murray M, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson J, Sumerauer D, Zapotocky M, Churackova M, Cyprova S, Zamecnik J, Malinova B, Kyncl M, Tichy M, Stary J, Lassen-Ramshad Y, von Oettingen G, Agerbaek M, Ohnishi T, Kohno S, Inoue A, Ohue S, Kohno S, Iwata S, Inoue A, Ohue S, Kumon Y, Ohnishi T, Acharya S, DeWees T, Shinohara E, Perkins S, Kato H, Fuji H, Nakasu Y, Ishida Y, Okawada S, Yang Q, Guo C, Chen Z, Alapetite C, Faure-Conter C, Verite C, Pagnier A, Laithier V, Entz-Werle N, Gorde-Grosjean S, Palenzuela G, Lemoine P, Frappaz D, Nguyen HA, Bui L, Ngoc, Cerbone M, Ederies A, Losa L, Moreno C, Sun K, Spoudeas HA, Nakano Y, Okada K, Kosaka Y, Nagashima T, Hashii Y, Kagawa N, Soejima T, Osugi Y, Sakamoto H, Hara J, Nicholson J, Alapetite C, Kortmann RD, Garre ML, Ricardi U, Saran F, Frappaz D, Calaminus G, Muda Z, Menon B, Ibrahim H, Rahman EJA, Muhamad M, Othman IS, Thevarajah A, Cheng S, Kilday JP, Laperriere N, Drake J, Bouffet E, Bartels U, Sakamoto H, Matsusaka Y, Watanabe Y, Umaba R, Hara J, Osugi Y, Alapetite C, Ruffier-Loubiere A, De Marzi L, Bolle S, Claude L, Habrand JL, Brisse H, Frappaz D, Doz F, Bourdeaut F, Dendale R, Mazal A, Fournier-Bidoz N, Fujimaki T, Fukuoka K, Shirahata M, Suzuki T, Adachi JI, Mishima K, Wakiya K, Matsutani M, Nishikawa R, Fukushima S, Yamashita S, Kato M, Nakamura H, Takami H, Suzuki T, Yanagisawa T, Mukasa A, Kumabe T, Nagane M, Sugiyama K, Tamura K, Narita Y, Shibui S, Shibata T, Ushijima T, Matsutani M, Nishikawa R, Ichimura K, Consortium IGA, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Czech T, Nicholson J, Frappaz D, Kortmann RD, Alapetite C, Garre ML, Ricardi U, Saran F, Calaminus G, Hayden J, Bartels U, Calaminus G, Joseph R, Nicholson J, Hale J, Lindsay H, Kogiso M, Qi L, Yee TW, Huang Y, Mao H, Lin F, Baxter P, Su J, Terashima K, Perlaky L, Lau C, Parsons D, Chintagumpala M, Li XAN, Osorio D, Vaughn D, Gardner S, Mrugala M, Ferreira M, Keene C, Gonzalez-Cuyar L, Hebb A, Rockhill J, Wang L, Yamaguchi S, Burstein M, Terashima K, Ng HK, Nakamura H, He Z, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adesina A, Sun J, Munzy D, Gibbs R, Leal S, Wheeler D, Lau C, Dhall G, Robison N, Judkins A, Krieger M, Gilles F, Park J, Lee SU, Kim T, Choi Y, Park HJ, Shin SH, Kim JY, Robison N, Dhir N, Khamani J, Margol A, Wong K, Britt B, Evans A, Nelson M, Grimm J, Finlay J, Dhall G. GERM CELL TUMOURS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Vaidyanathan G, Gururangan S, Bigner D, Zalutsky M, Morfouace M, Shelat A, Megan J, Freeman BB, Robinson S, Throm S, Olson JM, Li XN, Guy KR, Robinson G, Stewart C, Gajjar A, Roussel M, Sirachainan N, Pakakasama S, Anurathapan U, Hansasuta A, Dhanachai M, Khongkhatithum C, Hongeng S, Feroze A, Lee KS, Gholamin S, Wu Z, Lu B, Mitra S, Cheshier S, Northcott P, Lee C, Zichner T, Lichter P, Korbel J, Wechsler-Reya R, Pfister S, Project IPT, Li KKW, Xia T, Ma FMT, Zhang R, Zhou L, Lau KM, Ng HK, Lafay-Cousin L, Chi S, Madden J, Smith A, Wells E, Owens E, Strother D, Foreman N, Packer R, Bouffet E, Wataya T, Peacock J, Taylor MD, Ivanov D, Garnett M, Parker T, Alexander C, Meijer L, Grundy R, Gellert P, Ashford M, Walker D, Brent J, Cader FZ, Ford D, Kay A, Walsh R, Solanki G, Peet A, English M, Shalaby T, Fiaschetti G, Baulande S, Gerber N, Baumgartner M, Grotzer M, Hayase T, Kawahara Y, Yagi M, Minami T, Kanai N, Yamaguchi T, Gomi A, Morimoto A, Hill R, Kuijper S, Lindsey J, Schwalbe E, Barker K, Boult J, Williamson D, Ahmad Z, Hallsworth A, Ryan S, Poon E, Robinson S, Ruddle R, Raynaud F, Howell L, Kwok C, Joshi A, Nicholson SL, Crosier S, Wharton S, Robson K, Michalski A, Hargrave D, Jacques T, Pizer B, Bailey S, Swartling F, Petrie K, Weiss W, Chesler L, Clifford S, Kitanovski L, Prelog T, Kotnik BF, Debeljak M, Fiaschetti G, Shalaby T, Baumgartner M, Grotzer MA, Gevorgian A, Morozova E, Kazantsev I, Iukhta T, Safonova S, Kumirova E, Punanov Y, Afanasyev B, Zheludkova O, Grajkowska W, Pronicki M, Cukrowska B, Dembowska-Baginska B, Lastowska M, Murase A, Nobusawa S, Gemma Y, Yamazaki F, Masuzawa A, Uno T, Osumi T, Shioda Y, Kiyotani C, Mori T, Matsumoto K, Ogiwara H, Morota N, Hirato J, Nakazawa A, Terashima K, Fay-McClymont T, Walsh K, Mabbott D, Smith A, Wells E, Madden J, Chi S, Owens E, Strother D, Packer R, Foreman N, Bouffet E, Lafay-Cousin L, Sturm D, Northcott PA, Jones DTW, Korshunov A, Lichter P, Pfister SM, Kool M, Hooper C, Hawes S, Kees U, Gottardo N, Dallas P, Siegfried A, Bertozzi AI, Sevely A, Loukh N, Munzer C, Miquel C, Bourdeaut F, Pietsch T, Dufour C, Delisle MB, Kawauchi D, Rehg J, Finkelstein D, Zindy F, Phoenix T, Gilbertson R, Pfister S, Roussel M, Trubicka J, Borucka-Mankiewicz M, Ciara E, Chrzanowska K, Perek-Polnik M, Abramczuk-Piekutowska D, Grajkowska W, Jurkiewicz D, Luczak S, Kowalski P, Krajewska-Walasek M, Lastowska M, Sheila C, Lee S, Foster C, Manoranjan B, Pambit M, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, Hawkins C, Ramaswamy V, Bouffet E, Taylor M, Singhal A, Hukin J, Rassekh R, Yip S, Northcott P, Singh S, Duhman C, Dunn S, Chen T, Rush S, Fuji H, Ishida Y, Onoe T, Kanda T, Kase Y, Yamashita H, Murayama S, Nakasu Y, Kurimoto T, Kondo A, Sakaguchi S, Fujimura J, Saito M, Arakawa T, Arai H, Shimizu T, Lastowska M, Jurkiewicz E, Daszkiewicz P, Drogosiewicz M, Trubicka J, Grajkowska W, Pronicki M, Kool M, Sturm D, Jones DTW, Hovestadt V, Buchhalter I, Jager NN, Stuetz A, Johann P, Schmidt C, Ryzhova M, Landgraf P, Hasselblatt M, Schuller U, Yaspo ML, von Deimling A, Korbel J, Eils R, Lichter P, Korshunov A, Pfister S, Modi A, Patel M, Berk M, Wang LX, Plautz G, Camara-Costa H, Resch A, Lalande C, Kieffer V, Poggi G, Kennedy C, Bull K, Calaminus G, Grill J, Doz F, Rutkowski S, Massimino M, Kortmann RD, Lannering B, Dellatolas G, Chevignard M, Lindsey J, Kawauchi D, Schwalbe E, Solecki D, McKinnon P, Olson J, Hayden J, Grundy R, Ellison D, Williamson D, Bailey S, Roussel M, Clifford S, Buss M, Remke M, Lee J, Caspary T, Taylor M, Castellino R, Lannering B, Sabel M, Gustafsson G, Fleischhack G, Benesch M, Doz F, Kortmann RD, Massimino M, Navajas A, Reddingius R, Rutkowski S, Miquel C, Delisle MB, Dufour C, Lafon D, Sevenet N, Pierron G, Delattre O, Bourdeaut F, Ecker J, Oehme I, Mazitschek R, Korshunov A, Kool M, Lodrini M, Deubzer HE, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T, Phoenix T, Patmore D, Boulos N, Wright K, Boop S, Gilbertson R, Janicki T, Burzynski S, Burzynski G, Marszalek A, Triscott J, Green M, Foster C, Fotovati A, Berns R, O'Halloran K, Singhal A, Hukin J, Rassekh SR, Yip S, Toyota B, Dunham C, Dunn SE, Liu KW, Pei Y, Wechsler-Reya R, Genovesi L, Ji P, Davis M, Ng CG, Remke M, Taylor M, Cho YJ, Jenkins N, Copeland N, Wainwright B, Tang Y, Schubert S, Nguyen B, Masoud S, Gholamin S, Lee A, Willardson M, Bandopadhayay P, Bergthold G, Atwood S, Whitson R, Cheshier S, Qi J, Beroukhim R, Tang J, Wechsler-Reya R, Oro A, Link B, Bradner J, Cho YJ, Vallero SG, Bertin D, Basso ME, Milanaccio C, Peretta P, Cama A, Mussano A, Barra S, Morana G, Morra I, Nozza P, Fagioli F, Garre ML, Darabi A, Sanden E, Visse E, Stahl N, Siesjo P, Cho YJ, Vaka D, Schubert S, Vasquez F, Weir B, Cowley G, Keller C, Hahn W, Gibbs IC, Partap S, Yeom K, Martinez M, Vogel H, Donaldson SS, Fisher P, Perreault S, Cho YJ, Guerrini-Rousseau L, Dufour C, Pujet S, Kieffer-Renaux V, Raquin MA, Varlet P, Longaud A, Sainte-Rose C, Valteau-Couanet D, Grill J, Staal J, Lau LS, Zhang H, Ingram WJ, Cho YJ, Hathout Y, Brown K, Rood BR, Sanden E, Visse E, Stahl N, Siesjo P, Darabi A, Handler M, Hankinson T, Madden J, Kleinschmidt-Demasters BK, Foreman N, Hutter S, Northcott PA, Kool M, Pfister S, Kawauchi D, Jones DT, Kagawa N, Hirayama R, Kijima N, Chiba Y, Kinoshita M, Takano K, Eino D, Fukuya S, Yamamoto F, Nakanishi K, Hashimoto N, Hashii Y, Hara J, Taylor MD, Yoshimine T, Wang J, Guo C, Yang Q, Chen Z, Perek-Polnik M, Lastowska M, Drogosiewicz M, Dembowska-Baginska B, Grajkowska W, Filipek I, Swieszkowska E, Tarasinska M, Perek D, Kebudi R, Koc B, Gorgun O, Agaoglu FY, Wolff J, Darendeliler E, Schmidt C, Kerl K, Gronych J, Kawauchi D, Lichter P, Schuller U, Pfister S, Kool M, McGlade J, Endersby R, Hii H, Johns T, Gottardo N, Sastry J, Murphy D, Ronghe M, Cunningham C, Cowie F, Jones R, Sastry J, Calisto A, Sangra M, Mathieson C, Brown J, Phuakpet K, Larouche V, Hawkins C, Bartels U, Bouffet E, Ishida T, Hasegawa D, Miyata K, Ochi S, Saito A, Kozaki A, Yanai T, Kawasaki K, Yamamoto K, Kawamura A, Nagashima T, Akasaka Y, Soejima T, Yoshida M, Kosaka Y, Rutkowski S, von Bueren A, Goschzik T, Kortmann R, von Hoff K, Friedrich C, Muehlen AZ, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Faldum A, Kuehl J, Pietsch T, KRAMER K, -Taskar NP, Zanzonico P, Humm JL, Wolden SL, Cheung NKV, Venkataraman S, Alimova I, Harris P, Birks D, Balakrishnan I, Griesinger A, Remke M, Taylor MD, Handler M, Foreman NK, Vibhakar R, Margol A, Robison N, Gnanachandran J, Hung L, Kennedy R, Vali M, Dhall G, Finlay J, Erdrich-Epstein A, Krieger M, Drissi R, Fouladi M, Gilles F, Judkins A, Sposto R, Asgharzadeh S, Peyrl A, Chocholous M, Holm S, Grillner P, Blomgren K, Azizi A, Czech T, Gustafsson B, Dieckmann K, Leiss U, Slavc I, Babelyan S, Dolgopolov I, Pimenov R, Mentkevich G, Gorelishev S, Laskov M, Friedrich C, Warmuth-Metz M, von Bueren AO, Nowak J, von Hoff K, Pietsch T, Kortmann RD, Rutkowski S, Mynarek M, von Hoff K, Muller K, Friedrich C, von Bueren AO, Gerber NU, Benesch M, Pietsch T, Warmuth-Metz M, Ottensmeier H, Kwiecien R, Faldum A, Kuehl J, Kortmann RD, Rutkowski S, Mynarek M, von Hoff K, Muller K, Friedrich C, von Bueren AO, Gerber NU, Benesch M, Pietsch T, Warmuth-Metz M, Ottensmeier H, Kwiecien R, Faldum A, Kuehl J, Kortmann RD, Rutkowski S, Yankelevich M, Laskov M, Boyarshinov V, Glekov I, Pimenov R, Ozerov S, Gorelyshev S, Popa A, Dolgopolov I, Subbotina N, Mentkevich G, Martin AM, Nirschl C, Polanczyk M, Bell R, Martinez D, Sullivan LM, Santi M, Burger PC, Taube JM, Drake CG, Pardoll DM, Lim M, Li L, Wang WG, Pu JX, Sun HD, Remke M, Taylor MD, Ruggieri R, Symons MH, Vanan MI, Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher S, Zeid R, Masoud S, Yu F, Vue N, Gibson W, Paolella B, Mitra S, Cheshier S, Qi J, Liu KW, Wechsler-Reya R, Weiss W, Swartling FJ, Kieran MW, Bradner JE, Beroukhim R, Cho YJ, Maher O, Khatua S, Tarek N, Zaky W, Gupta T, Mohanty S, Kannan S, Jalali R, Kapitza E, Denkhaus D, Muhlen AZ, Rutkowski S, Pietsch T, von Hoff K, Pizer B, Dufour C, van Vuurden DG, Garami M, Massimino M, Fangusaro J, Davidson TB, da Costa MJG, Sterba J, Benesch M, Gerber NU, Mynarek M, Kwiecien R, Clifford SC, Kool M, Pietsch T, Finlay JL, Rutkowski S, Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones DT, Felsberg J, Goschzik T, Kool M, Northcott PA, von Hoff K, von Bueren A, Skladny H, Taylor M, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister S, Kunder R, Jalali R, Sridhar E, Moiyadi AA, Goel A, Goel N, Shirsat N, Othman R, Storer L, Korshunov A, Pfister SM, Kerr I, Coyle B, Law N, Smith ML, Greenberg M, Bouffet E, Taylor MD, Laughlin S, Malkin D, Liu F, Moxon-Emre I, Scantlebury N, Mabbott D, Nasir A, Othman R, Storer L, Onion D, Lourdusamy A, Grabowska A, Coyle B, Cai Y, Othman R, Bradshaw T, Coyle B, de Medeiros RSS, Beaugrand A, Soares S, Epelman S, Jones DTW, Hovestadt V, Wang W, Northcott PA, Kool M, Sultan M, Landgraf P, Reifenberger G, Eils R, Yaspo ML, Wechsler-Reya RJ, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P, Alderete D, Baroni L, Lubinieki F, Auad F, Gonzalez ML, Puya W, Pacheco P, Aurtenetxe O, Gaffar A, Gros L, Cruz O, Calvo C, Navajas A, Shinojima N, Nakamura H, Kuratsu JI, Hanaford A, Eberhart C, Archer T, Tamayo P, Pomeroy S, Raabe E, De Braganca K, Gilheeney S, Khakoo Y, Kramer K, Wolden S, Dunkel I, Lulla RR, Laskowski J, Fangusaro J, Goldman S, Gopalakrishnan V, Ramaswamy V, Remke M, Shih D, Wang X, Northcott P, Faria C, Raybaud C, Tabori U, Hawkins C, Rutka J, Taylor M, Bouffet E, Jacobs S, De Vathaire F, Diallo I, Llanas D, Verez C, Diop F, Kahlouche A, Grill J, Puget S, Valteau-Couanet D, Dufour C, Ramaswamy V, Thompson E, Taylor M, Pomeroy S, Archer T, Northcott P, Tamayo P, Prince E, Amani V, Griesinger A, Foreman N, Vibhakar R, Sin-Chan P, Lu M, Kleinman C, Spence T, Picard D, Ho KC, Chan J, Hawkins C, Majewski J, Jabado N, Dirks P, Huang A, Madden JR, Foreman NK, Donson AM, Mirsky DM, Wang X, Dubuc A, Korshunov A, Ramaswamy V, Remke M, Mack S, Gendoo D, Peacock J, Luu B, Cho YJ, Eberhart C, MacDonald T, Li XN, Van Meter T, Northcott P, Croul S, Bouffet E, Pfister S, Taylor M, Laureano A, Brugmann W, Denman C, Singh H, Huls H, Moyes J, Khatua S, Sandberg D, Silla L, Cooper L, Lee D, Gopalakrishnan V. MEDULLOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat 2014; 145:143-53. [PMID: 24682674 DOI: 10.1007/s10549-014-2907-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 03/04/2014] [Indexed: 10/25/2022]
Abstract
We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using multivariate analyses. The 3-year DFS rate was 87 % [95 % confidence interval (CI) 85-90]. The pathologic complete response (pCR: ypT0/is + ypN0) rate was 51 %. The pCR rate was higher in the ER/PgR-negative patients than in the ER/PgR-positive patients (64 vs. 36 %, P < 0.001). Patients with pCR showed a higher DFS rate than patients without pCR (93 vs. 82 %, P < 0.001). Multivariate analysis revealed three independent predictors for poorer DFS: advanced nodal stage [hazard ratio (HR) 2.63, 95 % CI 1.36-5.21, P = 0.004 for cN2-3 vs. cN0], histological/nuclear grade 3 (HR 1.81, 95 % CI 1.15-2.91, P = 0.011), and non-pCR (HR 1.98, 95 % CI 1.22-3.24, P = 0.005). In the ER/PgR-negative dataset, non-pCR (HR 2.63, 95 % CI 1.43-4.90, P = 0.002) and clinical tumor stage (HR 2.20, 95 % CI 1.16-4.20, P = 0.017 for cT3-4 vs. cT1-2) were independent predictors for DFS, and in the ER/PgR-positive dataset, histological grade of 3 (HR 3.09, 95 % CI 1.48-6.62, P = 0.003), clinical nodal stage (HR 4.26, 95 % CI 1.53-13.14, P = 0.005 for cN2-3 vs. cN0), and young age (HR 2.40, 95 % CI 1.12-4.94, P = 0.026 for ≤40 vs. >40) were negative predictors for DFS. Strict pCR (ypT0 + ypN0) was an independent predictor for DFS in both the ER/PgR-negative and -positive datasets (HR 2.66, 95 % CI 1.31-5.97, P = 0.006 and HR 3.86, 95 % CI 1.13-24.21, P = 0.029, respectively). These results may help assure a more accurate prognosis and personalized treatment for HER2-positive breast cancer patients.
Collapse
Affiliation(s)
- M Takada
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kosaka Y, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Enomoto T, Kuranami M, Tanino H, Watanabe M. Abstract P3-09-03: Final result of randomised controlled phase II study of the efficiency of palonosetron, aprepitant, and dexamethasone for day1 with or without dexamethasone on days2 and 3. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-09-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Emesis is one of the major non-hematologic toxicity caused by chemotherapy. The control of Chemotherapy Induced Nausea and Vomiting (CINV) is conducted to a life lengthening. Recently, CINV is controlled by the second generation 5-HT3 receptor blocker (Palonosetron; PALO) and a NK-1 receptor antagonist (Aprepitant; APR). It has been shown that dexamethasone (DEX) with 5-HT3 receptor blocker improves acute / delayed CINV. However, it has not been determined the medication schedule for DEX with PALO and APR. The purpose of this study is evaluated the efficiency of palonosetron, aprepitant and dexamethasone for day1 with or without dexamethasone on days2 and 3. This is final result of current study.
Methods: Breast cancer patients who administered anthracyclin drug regimen have been eligible from April, 2011 to June, 2013. The patients were randomised to group A (PALO/APR/DEX one day) and group B (PALO/APR/DEX three days).
Trial designAprepitant125mg80mg80mg Palonosetron0.75mg dexamethasone9.9mg6.6 mg or placebo6.6 mg or placebo Chemotherapydo days12345
Eighty patients were estimate as study samples. The primary endpoint was a complete response (CR) rate of vomiting, the secondary endpoint was a complete control (CC) rate of vomiting.
Results: Eighty two patients were enrolled in this study. There was not inferiority about CR rate of five days after chemotherapy (81.1% of group A, 82.1% of group B). CC rate of group A (62.2%) was better than that of group B (46.2%). However, CC rate was no significant difference between group A and B. There was no significant difference about any level of nausea between group A and B.
Conclusions: One day of dexamethasone with Palonosetron and Aprepitant treatment is enough to control the emesis of high emetogenic chemotherapeutic agents.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-09-03.
Collapse
Affiliation(s)
- Y Kosaka
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Sengoku
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Minatani
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kikuchi
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Nishimiya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Waraya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - T Enomoto
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kuranami
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Tanino
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Watanabe
- Kitasato University School of Medicine, Sagamihara, Japan
| |
Collapse
|
26
|
Ishikawa T, Shimizu D, Tanabe M, Oba MS, Sasaki T, Morita S, Kida K, Nawata S, Mogami M, Doi T, Tsugawa K, Ogata H, Kosaka Y, Sengoku N, Saito Y, Suzuki Y, Suto A, Chishima T, Ichikawa Y, Endo I, Tokuda Y. Abstract P3-14-08: A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-14-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Taxane-based regimens have been developed and used widely to treat breast cancer. It has therefore become important to identify subgroups of patients in which anthracyclines are indispensable. Pathological response to neoadjuvant chemotherapy (NAC) predicts prognosis in hormone-negative subtypes. We therefore initiated a randomized phase II NAC study to compare a taxane with and without an anthracycline in these breast-cancer subtypes.
Aim: To determine the safety and activity of six cycles of docetaxel and cyclophosphamide (TC6) compared with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D), and to examine the predictive factors for each regimen.
Methods: Eligibility criteria were operable hormone-receptor-negative breast cancer, age younger than 75 years and ECOG PS0-1. According to HER2 status, patients were randomly assigned to TC (75/600 mg/m2) every 3 weeks X 6 or FEC (500/100/500 mg/m2) every 3 weeks X 3 followed by D (100 mg/m2) every 3 weeks X 3. The primary endpoint was the rate of pathological complete response (pCR; grade 3). Triple-negative (TN) breast cancer was subdivided by cytokeratin 5/6 and epidermal growth factor receptor into basal- and non-basal subtypes. Secondary endpoints were safety, breast-conserving surgery, disease-free survival, overall survival, and predictive factors: Ki-67, p53, aldehyde dehydrogenase (ALDH) 1 and topoisomerase 2A by both immunohistochemistry and fluorescence in situ hybridization for each regimen.
Results: Ninety-seven of 103 patients were analyzed successfully (50 for FEC-D and 47 for TC6). Significantly more severe adverse events (grade 2) were observed in FEC-D-treated patients (poor appetite, nausea and vomiting: p = 0.001; febrile neutropenia: p = 0.016). The pCR rate tended to be higher in FEC-D-treated patients compared with TC6-treated patients (pCR: 36.0 vs. 25.5%, n.s.). FEC-D treatment was significantly more effective than TC6 in basal-type (p = 0.033) but not in non-basal and HER2 subtypes. ALDH1 was associated with resistance to both regimens (FEC-D: p = 0.047, TC6: p = 0.085)
Conclusions: TC6 was safer, but not more effective than FEC-D. TC6 was significantly less active than FEC-D in basal subtype, and equivalent to FEC-D in HER2 and non-basal subtypes. Concurrent use of trastuzumab with TC could thus represent a reasonable option for NAC in HER2-subtype patients. ALDH1 could provide a marker for novel strategies such as stem cell-based therapies for breast cancer. Analyses on pathological factors in surgical specimens after NAC will be presented at the meeting.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-14-08.
Collapse
Affiliation(s)
- T Ishikawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - D Shimizu
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Tanabe
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - MS Oba
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Sasaki
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Morita
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Kida
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - S Nawata
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - M Mogami
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Doi
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - K Tsugawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - H Ogata
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Kosaka
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - N Sengoku
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Saito
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Suzuki
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - A Suto
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - T Chishima
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Ichikawa
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - I Endo
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| | - Y Tokuda
- Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan; Shonan-Kinen Hospital, Kamakura, Kanagawa, Japan; Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Kitasato University, Sagamihara, Kanagawa, Japan; Endocrine and Breast Surgery, Tokai University, Isehara, Kanagawa, Japan; Clinical Oncology and Gastrointestinal Surgery, Yokohama City University, Yokohama, Kanagawa, Japan
| |
Collapse
|
27
|
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND:
Addition of trastuzumab to neoadjuvant chemotherapy (NAC) improved pathologic complete response (pCR) rate in HER2-positive breast cancer. Although recent trials have shown favorable prognosis with NAC plus trastuzumab, clinicopathological factors to predict the outcome have not been fully understood. The aim of this study was to investigate the survival after NAC with trastuzumab and to explore the predictive factors.
PATIENTS AND METHODS:
This is a multicenter retrospective observational study. Patients with HER2-positive primary breast cancer treated with NAC plus trastuzumab from 2001 to 2010 were identified from the institutional database. Primary end point was disease-free survival (DFS). pCR was defined as ypT0/is+ypN0. Kaplan-Meier method was used to estimate DFS. Logistic regression and proportional hazard analysis were used to identify clinicopathological factors to predict pCR and DFS, respectively.
RESULTS:
733 patients were included in the analysis (whole dataset). 425 were ER/PgR-negative (HR- dataset) and 306 were ER/PgR-positive (HR+ dataset). Radiation therapy was performed in 90% of lumpectomy and 31% of mastectomy. Hormonal therapy was performed in 84% of HR+ dataset. pCR rate was 45% in whole dataset, 60% in HR- dataset, and 34% in HR+ dataset. Table 1 showed the result of multivariate analysis for pCR in whole dataset. When HR+ and HR- dataset were analyzed separately, no definitive predictors for pCR were identified in multivariate analysis. Although the patients with pCR showed a significantly favorable prognosis than those without pCR at 3 years DFS, in whole dataset (93% vs 83%, p<0.0001) and HR- dataset (94% vs 80%, p<0.0001), there was no significant difference in HR+ dataset (89% vs 86%, p = 0.10). Different predictors were selected for DFS when multivariate analysis was conducted separately between HR- and HR+ dataset (Table 2).
CONCLUSIONS:
In this observational study, we clarified predictors for pCR and DFS in HER2-positive patients treated with neoadjuvant trastuzumab containing therapy based on tumor subtype. Our results may help us to predict the prognosis more precisely and to simulate the disease course.
Table 1) Multivariate logistic regression analysis for pCR in whole datasetFactorsOR95%CIp-valuePost- vs Pre-menopause1.50(1.05-2.15)0.026*cT1-2 vs cT3-41.72(1.16-2.59)0.008*ER/PgR-negative vs ER/PgR-positive3.32(2.30-4.82)<0.0001*Grade 3 vs 1-21.28(0.89-1.84)0.183
Table 2) Multivariate proportional hazard analysis for DFSFactors†HR95%CIp-valueWhole dataset Pre- vs Post-menopause1.61(1.04-2.52)0.033*cN2-3 vs cN03.06(1.58-6.24)0.001*cN1 vs cN02.26(1.23-4.41)0.007*Grade 3 vs 1-21.87(1.20-2.97)0.006*non-pCR vs pCR1.90(1.18-3.13)0.008*HR- dataset Pre- vs Post-menopause1.70(1.01-2.85)0.046*cT3-4 vs cT1-21.86(1.09-3.17)0.024*non-pCR vs pCR3.28(1.90-5.87)<0.0001*HR+ dataset cN2-3 vs cN05.01(1.79-16.19)0.002*cN1 vs cN03.50(1.40-10.61)0.006*Grade 3 vs 1-22.95(1.52-5.87)0.001*†Only factors with statistical significance
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-20.
Collapse
Affiliation(s)
- M Takada
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Ishiguro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Nagai
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohtani
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Kawabata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Yanagita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Hozumi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - C Shimizu
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Takao
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Sato
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Kosaka
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Sagara
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Iwata
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Ohno
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - K Kuroi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - N Masuda
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Yamashiro
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Sugimoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Kondo
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - Y Naito
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - H Sasano
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - T Inamoto
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - S Morita
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| | - M Toi
- Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University
| |
Collapse
|
28
|
Sakamoto T, Kosaka Y, Yasukochi S, Takigiku K, Tazawa S, Harada Y. Mid-term neurodevelopmental outcome in children with HLHS and related anomalies. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p2083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Sakamoto T, Kosaka Y, Yasukochi S, Takigiku K, Tazawa S, Harada Y. Aggressive catheter and surgical intervention for recoarctation after Norwood operation results in excellent long-term outcome. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.1714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
30
|
Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Amano K, Takedani H, Tamashima S, Matsushita T, Tawa A, Tanaka I, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Kawakami K, Ohashi Y, Saito H. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia 2013; 19:853-60. [DOI: 10.1111/hae.12205] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/13/2013] [Indexed: 11/29/2022]
Affiliation(s)
- A. Shirahata
- Kitakyushu Yahata Higashi Hospital; Kitakyushu Fukuoka
| | - K. Fukutake
- Department of Laboratory Medicine; Tokyo Medical University; Tokyo
| | - J. Takamatsu
- Japanese Red Cross Aichi Blood Center; Seto Aichi
| | - M. Shima
- Department of Paediatrics; Nara Medical University; Kashihara Nara
| | - H. Hanabusa
- Department of Haematology; Ogikubo Hospital; Tokyo
| | - H. Mugishima
- Department of Paediatrics; Nihon University Itabashi Hospital; Tokyo
| | - K. Amano
- Department of Laboratory Medicine; Tokyo Medical University; Tokyo
| | - H. Takedani
- Department of Joint Surgery; Research Hospital of the Institute of Medical Science; The University of Tokyo; Tokyo
| | - S. Tamashima
- Department of Haematology and Oncology; Seirei Hamamatsu General Hospital; Hamamatsu Shizuoka
| | - T. Matsushita
- Department of Transfusion Medicine; Nagoya University Hospital; Nagoya
| | - A. Tawa
- Department of Paediatrics; National Hospital Organization Osaka National Hospital; Osaka
| | - I. Tanaka
- Department of Paediatrics; Nara Medical University; Kashihara Nara
| | - S. Higasa
- Division of Haematology; Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Hyogo
| | - Y. Kosaka
- Department of Haematology and Oncology; Kobe Children's Hospital; Kobe
| | - T. Fujii
- Division of the Blood Transfusion; Hiroshima University Hospital; Hiroshima
| | - M. Sakai
- Department of Paediatrics; University of Occupational and Environmental Health; Kitakyushu Fukuoka
| | - M. Migita
- Department of Paediatrics; Kumamoto Red Cross Hospital; Kumamoto
| | - K. Kawakami
- Department of Paediatrics; Kagoshima City Hospital; Kagoshima
| | - Y. Ohashi
- Department of Biostatistics; School of Public Health; The University of Tokyo; Tokyo
| | - H. Saito
- National Hospital Organization Nagoya Medical Center; Nagoya Japan
| |
Collapse
|
31
|
Kosaka Y, Sengoku N, Kikuchi M, Nishimiya H, Enomoto T, Kuranami M, Watanabe M. Abstract P2-12-13: Results of randomised controlled phase II study (KBCSG02 trial) of the efficiency of palonosetron, aprepitant, and dexamethasone for day1 with or without dexamethasone on days2 and 3. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-12-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Emesis is one of the major non-hematologic toxicity caused by chemotherapy. The control of Chemotherapy Induced Nausea and Vomiting (CINV) is conducted to a life lengthening. Recently, CINV is controlled by the second generation 5-HT3 receptor blocker (Palonosetron; PALO) and a NK-1 receptor antagonist (Aprepitant; APR). It has been shown that dexamethasone (DEX) with 5-HT3 receptor blocker improves acute/delayed CINV. However, it has not been determined the medication schedule of DEX with PALO and APR. The purpose of this study is evaluated the efficiency of palonosetron, aprepitant and dexamethasone for day1 with or without dexamethasone on days2 and 3.
Methods: Breast cancer patients who administered anthracyclin drug regimen have been eligible from April, 2011 to June, 2012. The patients were randomised to group A (PALO/APR/DEX one day) and group B (PALO/APR/DEX three days). Eighty patients was estimate as study samples. The primary endpoint was a complete response (CR) rate of vomiting, the secondary endpoint was a complete control (CC) rate of vomiting.
Results: Forty patients were enrolled in this study, and patient recruitment is continued. CR rate was no significant difference in both groups (76.9% of group A, 73.3% of group B). CC rate of group A (61.5%) did not show inferiority compared with group B (40.0%).
Conclusions: In this current study, we suggest that one day dexamethasone treatment could reduce enough the emesis of high emetogenic chemotherapeutic agents.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-12-13.
Collapse
Affiliation(s)
- Y Kosaka
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Sengoku
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kikuchi
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Nishimiya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - T Enomoto
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kuranami
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Watanabe
- Kitasato University School of Medicine, Sagamihara, Japan
| |
Collapse
|
32
|
Kishi T, Kokubo M, Takayama K, Kosaka Y, Okuno Y, Fujita S, Kaji R, Hata A, Tomii K, Katakami N. Feasibility of Definitive Concurrent Chemoradiation Therapy for Patients Over 80 Years Old With Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Kosaka Y, Kin H, Tatetsu M, Uema I, Takayama C. Distinct development of GABA system in the ventral and dorsal horns in the embryonic mouse spinal cord. Brain Res 2012; 1486:39-52. [PMID: 23044470 DOI: 10.1016/j.brainres.2012.10.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2012] [Revised: 09/25/2012] [Accepted: 10/01/2012] [Indexed: 10/27/2022]
Abstract
In the adult brain, γ-amino butyric acid (GABA) is an inhibitory neurotransmitter, whereas it acts as an excitatory transmitter in the immature brain, and may be involved in morphogenesis. In the present study, we immunohistochemically examined the developmental changes in GABA signaling in the embryonic mouse cervical spinal cord. Glutamic acid decarboxylase and GABA were markers for GABA neurons. Vesicular GABA transporter was a marker for GABAergic and glycinergic terminals. Potassium chloride cotransporter 2 was a marker for GABAergic inhibition. We found five points: (1) In the ventral part, GABA neurons were divided into three groups. The first differentiated group sent commissural axons after embryonic day 11 (E11), but disappeared or changed their transmitter by E15. The second and third differentiated groups were localized in the ventral horn after E12, and sent axons to the ipsilateral marginal zone. There was a distal-to-proximal gradient in varicosity formation in GABAergic axons and a superficial-to-deep gradient in GABAergic synapse formation in the ventral horn; (2) In the dorsal horn, GABA neurons were localized after E13, and synapses were diffusely formed after E15; (3) GABA may be excitatory for several days before synapses formation; (4) There was a ventral-to-dorsal gradient in the development of GABA signaling. The GABAergic inhibitory network may develop in the ventral horn between E15 and E17, and GABA may transiently play crucial roles in inhibitory regulation of the motor system in the mouse fetus; (5) GABA signaling continued to develop after birth, and GABAergic system diminished in the ventral horn.
Collapse
Affiliation(s)
- Yoshinori Kosaka
- Department of Molecular Anatomy, School of Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa 9030215, Japan
| | | | | | | | | |
Collapse
|
34
|
Kosaka Y, Quillinan N, Bond C, Traystman R, Hurn P, Herson P. GPER1/GPR30 activation improves neuronal survival following global cerebral ischemia induced by cardiac arrest in mice. Transl Stroke Res 2012; 3:500-507. [PMID: 23483801 DOI: 10.1007/s12975-012-0211-8] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Female sex steroids, particularly estrogens, contribute to the sexually dimorphic response observed in cerebral ischemic outcome, with females being relatively protected compared to males. Using a mouse model of cardiac arrest and cardiopulmonary resuscitation (CA/CPR), we previously demonstrated that estrogen neuroprotection is mediated in part by the estrogen receptor β, with no involvement of estrogen receptor α. In this study we examined the neuroprotective effect of the novel estrogen receptor, G-protein coupled estrogen receptor 1 (GPER1/GPR30). Male mice administered the GPR30 agonist G1 exhibited significantly reduced neuronal injury in the hippocampal CA1 region and striatum. The magnitude of neuroprotection observed in G1 treated mice was indistinguishable from estrogen treated mice, implicating GPR30 in estrogen neuroprotection. Real-time quantitative RT-PCR indicates that G1 treatment increases expression of the neuroprotective ion channel, small conductance calcium-activated potassium channel 2. We conclude that GPR30 agonists show promise in reducing brain injury following global cerebral ischemia.
Collapse
Affiliation(s)
- Y Kosaka
- Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239
| | | | | | | | | | | |
Collapse
|
35
|
Yamauchi Y, Kosaka Y, Nobuta Y, Hino T, Nishimura K. Removal of Deuterium Retained in B, Ti, and TiO 2 by Neon Glow Discharge. Fusion Science and Technology 2012. [DOI: 10.13182/fst12-a14114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Yamauchi
- Faculty of Engineering, Hokkaido University, Kita-13, Nishi-8, Kita-ku, Sapporo, Hokkaido 060-8628, Japan
| | - Y. Kosaka
- Graduate School of Engineering, Hokkaido University, Kita-13, Nishi-8, Kita-ku, Sapporo, Hokkaido 060-8628, Japan
| | - Y. Nobuta
- Faculty of Engineering, Hokkaido University, Kita-13, Nishi-8, Kita-ku, Sapporo, Hokkaido 060-8628, Japan
| | - T. Hino
- Faculty of Engineering, Hokkaido University, Kita-13, Nishi-8, Kita-ku, Sapporo, Hokkaido 060-8628, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6, Oroshi-cho, Toki, Gifu 509-5292, Japan
| |
Collapse
|
36
|
Abdel-Mota F, El-Zayat S, Kosaka Y, El-Sayed M, Nassar M, Ito SI. Four Novel Ustilaginomycetous Anamorphic Yeast Species Isolated as Endophytes from the Medicinal Plant Hyoscyamus muticus. ACTA ACUST UNITED AC 2009. [DOI: 10.3923/ajps.2009.526.535] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
37
|
Kosaka Y, Takayama C. Developmental change in GABA signaling in the mouse cervical spinal cord. Neurosci Res 2009. [DOI: 10.1016/j.neures.2009.09.1095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Kita Y, Fukagawa T, Mimori K, Kosaka Y, Ishikawa K, Aikou T, Natsugoe S, Sasako M, Mori M. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Br J Cancer 2008; 100:153-9. [PMID: 19050704 PMCID: PMC2634681 DOI: 10.1038/sj.bjc.6604806] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Urokinase-type plasminogen activator receptor (uPAR) plays a central role in the plasminogen activation cascade and participates in extracellular matrix degradation, cell migration and invasion. We evaluated the expression level of uPAR mRNA and the presence of isolated tumour cells (ITCs) in bone marrow (BM) and peripheral blood (PB) in gastric cancer patients and clarified its clinical significance. We assessed specific uPAR mRNA expression by quantitative real-time reverse transcriptase- polymerase chain reaction (RT–PCR) in BM and PB in 846 gastric cancer patients as well as three epithelial cell markers, carcinoembryonic antigen (CEA), cytokeratin (CK)-19 and CK-7. The uPAR mRNA expression in bone marrow and peripheral blood expressed significantly higher than normal controls (P<0.0001). The uPAR mRNA in BM showed concordant expression with the depth of tumour invasion, distant metastasis, and the postoperative recurrence (P=0.015, 0.044 and 0.010, respectively); whereas in PB, we observed more intimate significant association between uPAR expression and clinicopathologic variables, such as depth of tumour invasion, the distant metastasis, the venous invasion and the clinical stage (P=0.009, 0.002, 0.039 and 0.008, respectively). In addition, the uPAR mRNA expression in PB was an independent prognostic factor for distant metastasis by multivariate analysis. We disclosed that it was possible to identify high-risk patients for distant metastasis by measuring uPAR mRNA especially in peripheral blood at the timing of operation in gastric cancer patients.
Collapse
Affiliation(s)
- Y Kita
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Kajihara N, Asou T, Takeda Y, Kosaka Y, Miyata D, Nagafuchi H, Yasui S. Impact of 3-mm Blalock-Taussig shunt in neonates and infants with a functionally single ventricle. Interact Cardiovasc Thorac Surg 2008; 8:211-5. [DOI: 10.1510/icvts.2008.187963] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
40
|
Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, Kosaka Y, Oda T, Oda M, Hayashi Y, Eguchi M, Horibe K, Nakahata T, Mizutani S, Ishii E. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007; 21:2258-63. [PMID: 17690691 DOI: 10.1038/sj.leu.2404903] [Citation(s) in RCA: 101] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We evaluated the efficacy of a treatment strategy in which infants with acute lymphoblastic leukemia (ALL) were stratified by their MLL gene status and then assigned to different risk-based therapies. A total of 102 patients were registered on two consecutive multicenter trials, designated MLL96 and MLL98, between 1995 and 2001. Those with a rearranged MLL gene (MLL-R, n=80) were assigned to receive intensive chemotherapy followed by hematopoietic stem cell transplantation (HSCT), while those with germline MLL (MLL-G, n=22) were treated with chemotherapy alone. The 5-year event-free survival (EFS) rate for all 102 infants was 50.9% (95% confidence interval, 41.0-60.8%). The most prominent late effect was growth impairment, observed in 58.9% of all evaluable patients in the MLL-R group. This plan of risk-based therapy appears to have improved the overall prognosis for infants with ALL, compared with previously reported results. However, over half the events in patients with MLL rearrangement occurred before the instigation of HSCT, and that HSCT-related toxic events comprised 36.3% (8/22) of post-transplantation events, suggesting that further stratification within the MLL-R group and the development of more effective early-phase intensification chemotherapy will be needed before the full potential of this strategy is realized.
Collapse
Affiliation(s)
- D Tomizawa
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Matsumoto M, Kawa K, Uemura M, Kato S, Ishizashi H, Isonishi A, Yagi H, Park YD, Takeshima Y, Kosaka Y, Hara H, Kai S, Kanamaru A, Fukuhara S, Hino M, Sako M, Hiraoka A, Ogawa H, Hara J, Fujimura Y. Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. Bone Marrow Transplant 2007; 40:251-9. [PMID: 17549054 DOI: 10.1038/sj.bmt.1705724] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We initially conducted a multicenter, randomized trial (n=43), and subsequently a questionnaire study (n=209) of participating hospitals, to evaluate whether infused fresh frozen plasma (FFP) could prevent the occurrence of hepatic veno-occlusive disease (VOD) after stem cell transplantation (SCT). Forty-three patients were divided into two groups: 23 receiving FFP infusions and 20 not receiving it. VOD developed in three patients not receiving FFP. Plasma von Willebrand factor (VWF) antigen levels were lower at days 0, 7 and 28 after SCT in patients receiving FFP than in those not receiving it, whereas plasma ADAMTS13 activity (ADAMTS13:AC) did not differ between them. Plasma VWF multimer (VWFM) was demonstrated to be defective in the high approximately intermediate VWFM during the early post-SCT phase, but there was a significant increase in high VWFM just before VOD onset. This suggests that a relative enzyme-to-substrate (ADAMTS13/high-VWFM) imbalance is involved in the pathogenesis of VOD. To strengthen this hypothesis, the incidence of VOD was apparently lower in patients receiving FFP infusions than in those not receiving it (0/23 vs 3/20) in the randomized trial. Further, the results combined with the subsequent questionnaire study (0/36 vs 11/173) clearly showed the incidence to be statistically significant (0/59 vs 14/193, P=0.033).
Collapse
Affiliation(s)
- M Matsumoto
- Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Kosaka Y, Mimori K, Fukagawa T, Ishikawa K, Etoh T, Katai H, Sano T, Watanabe M, Sasako M, Mori M. Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-1 overexpression in peripheral blood. Br J Cancer 2007; 96:1723-8. [PMID: 17486129 PMCID: PMC2359929 DOI: 10.1038/sj.bjc.6603785] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Identification of an isolated tumour cell with metastatic ability is important for predicting the recurrence and prognosis of gastric cancer. A biological marker for evaluating the metastatic ability of gastric cancer cells has not yet been identified. We assessed vascular endothelial growth factor receptor-1 mRNA expression by quantitative real-time reverse transcriptase-polymerase chain reaction. Vascular endothelial growth factor receptor-1 mRNA in peripheral blood was more highly expressed in perioperative metastasis-positive and postoperative recurrence cases than in normal control cases, early cancer cases and nonmetastatic advanced cancer cases. The peripheral blood vascular endothelial growth factor receptor-1 mRNA-positive group was associated with advanced clinical stage, deep invasion beyond the muscularis propria, lymphatic involvement, vascular involvement, lymph node metastasis, positive peritoneal lavage cytology, preoperative metastasis and postoperative recurrence. Flow cytometry analysis disclosed that vascular endothelial growth factor receptor-1 expressing cells in the peripheral blood were more abundant in cancer cases with metastases than in cases without metastases. Our data suggest that the amount of positive cells may provide information on the clinical features of gastric cancer, especially in regard to gastric cancer metastasis.
Collapse
Affiliation(s)
- Y Kosaka
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
- Department of Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara 228-8555, Japan
| | - K Mimori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | - T Fukagawa
- Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku 104-0045, Japan
| | - K Ishikawa
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
| | - T Etoh
- Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku 104-0045, Japan
| | - H Katai
- Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku 104-0045, Japan
| | - T Sano
- Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku 104-0045, Japan
| | - M Watanabe
- Department of Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara 228-8555, Japan
| | - M Sasako
- Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku 104-0045, Japan
| | - M Mori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546, Tsurumihara, Beppu 874-0838, Japan
- E-mail:
| |
Collapse
|
43
|
Kobayashi N, Ando M, Kosaka Y, Yong C, Okitsu T, Arata T, Ikeda H, Kobayashi K, Ueda T, Kurabayashi Y, Tanaka N. Partial hepatectomy and subsequent radiation facilitates engraftment of mouse embryonic stem cells in the liver. Transplant Proc 2004; 36:2352-4. [PMID: 15561246 DOI: 10.1016/j.transproceed.2004.08.141] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
For liver-targeted regenerative medicine, embryonic stem (ES) cell-derived hepatocyte-like cells proffer great expectation. In vitro exposure to a combination of various growth factors, such as hepatocyte growth factor and fibroblast growth factor-4, as well as cytokines, leads to differentiation of ES cells into hepatocyte-like cells. We sought to determine the in vivo environment that allowed engraftment of ES cells transplanted to the liver. Thus, we examined the effect of partial hepatectomy (50%) (PHT) and subsequent radiation (RT) of the male Balb/c mouse host liver on ES cell engraftment. ES cells (5 x 10(6)) derived from 129Sv mice were transplanted into the residual liver. The controls were ES cells transplanted into a normal liver. Bromo-deoxy-residine (BrdU)-uptake was performed to evaluate the effect of hepatectomy and RT on hepatocyte regeneration. Mouse ES cells engrafted, forming teratomas in the normal liver without showing any mononuclear infiltration. A liver modified by PHT and RT facilitated engraftment of mouse ES cells compared with a normal liver. Hepatic RT significantly suppressed hepatocytic uptake of BrdU.
Collapse
Affiliation(s)
- N Kobayashi
- Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Kobayashi N, Arata T, Okitsu T, Ikeda H, Kobayashi K, Kosaka Y, Narushima M, Tanaka N, Lakey JRT. Transduction of human islets with the lentiviral vector. Transplant Proc 2004; 36:2203-4. [PMID: 15518800 DOI: 10.1016/j.transproceed.2004.08.140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Establishment of an efficient gene delivery system for human pancreatic beta cells is important for the development of diabetes-targeted cell therapies. The human immunodeficiency virus type 1 (HIV-1)-derived lentiviral vector is well documented to be an effective gene transfer tool for various types of cells. Thus, we examined the efficiency of lentivirus-mediated gene delivery for human islets. Human islets were isolated using defined protocols for enzymatic dissociation and purification using discontinuous Ficoll gradients with a refrigerated Cobe 2991 machine. Isolated islets were shipped to Japan, cryopreserved for 3 months, and then subjected to transduction. A vesicular stomatitis virus G-protein (VSV-G)-pseudotyped lentiviral vector LtV-NLS/LacZ was produced in 293T cells under the Fugene6 method. 804G extracellular matrices were applied for monolayer formation of islets. Detection of NLS/LacZ expression was performed using X-gal staining. Lentiviral transduction was effective in these monolayer islets.
Collapse
Affiliation(s)
- N Kobayashi
- Department of Surgery, Okayama University Medical School, Okayama, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Imashuku S, Terui K, Matsuyama T, Asami K, Tsuchiya S, Ishii E, Kawa K, Kosaka Y, Eguchi H, Tsuchida M, Ikuta K, Kato S, Koizumi S, Okamura J, Morimoto A, Hibi S, Hamaoka K. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan. Bone Marrow Transplant 2003; 31:1127-35. [PMID: 12796792 DOI: 10.1038/sj.bmt.1704067] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The clinical utility of minimal residual disease (MRD) measurements following allogeneic stem cell transplantation (SCT) in childhood ALL is controversial. We therefore performed a multi-institutional study of MRD in bone marrow samples taken before SCT and at 1, 3, 6 and 12 months after SCT. Case-specific clonal rearrangements of IgH and TCR genes and expression levels of Wilms' tumor 1 (WT1) mRNA were determined by PCR or RT-PCR methods. In total, 95 cases met all criteria for analysis of informative IgH/TCR markers and quantitative WT1 mRNA expression levels. During the 2-year (median 414 days) study period, 20 patients relapsed. Although the proportion of patients with a positive IgH/TCR result before SCT was significantly reduced at 1 month after treatment (P<0.001), attesting the efficacy of SCT, serial measurements of IgH/TCR rearrangements did not correlate with leukemic relapse. Clonal switch was demonstrated in 11 of the 14 patients with bone marrow relapse, indicating that the poor predictive power of the MRD assay most likely reflected the loss of PCR targets. WT1 expression was not related to either MRD detection by IgH/TCR assays or to clinical leukemic relapse. The clinical value of serial MRD monitoring would be limited in ALL patients undergoing SCT.
Collapse
Affiliation(s)
- S Imashuku
- Kyoto City Institute of Health and Environmental Sciences, Kyoto, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Maruyama M, Kobayashi N, Okitsu T, Totsugawa T, Watanabe T, Matsumura T, Kosaka Y, Tanaka N. Successful lentivirus-based delivery of NLS-LACZ gene into porcine hepatocytes. Transplant Proc 2003; 35:435-6. [PMID: 12591476 DOI: 10.1016/s0041-1345(02)03793-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- M Maruyama
- Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Kobayashi N, Okitsu T, Maruyama M, Totsugawa T, Kosaka Y, Hayashi N, Nakaji S, Tanaka N. Development of a cellulose-based microcarrier containing cellular adhesive peptides for a bioartificial liver. Transplant Proc 2003; 35:443-4. [PMID: 12591480 DOI: 10.1016/s0041-1345(02)03783-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- N Kobayashi
- Department of Surgery, Okayama University Medical School, Okayama, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Kobayashi N, Kunieda T, Sakaguchi M, Okitsu T, Totsugawa T, Maruyama M, Kosaka Y, Takesue M, Shibata N, Tanaka N. Active expression of p21 facilitates differentiation of immortalized human hepatocytes. Transplant Proc 2003; 35:433-4. [PMID: 12591475 DOI: 10.1016/s0041-1345(02)03784-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- N Kobayashi
- Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Hibino N, Imai Y, Shin-oka T, Aoki M, Watanabe M, Kosaka Y, Matsumura G, Konuma T, Toyama S, Murata A, Naito Y, Miyake T. [First successful clinical application of tissue engineered blood vessel]. Kyobu Geka 2002; 55:368-73. [PMID: 11995317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
With this tissue engineering (TE) technique, the peripheral pulmonary artery was successfully reconstructed, using the patient's own venous cells in a 4-year-old girl, 2 years after Fontan procedure. A 4-year-old girl was given a diagnosis of single right ventricle, double-outlet right ventricle and pulmonary atresia. She underwent left modified Blalock-Taussig shunt at a month old, pulmonary artery angioplasty at a year and 3 months old, and bidirectional cavopulmonary shunt at 2 years and a month old. She underwent again pulmonary artery angioplasty and Fontan operation at 3 years and 3 months. An angiographical examination 7 months after the operation revealed total occlusion of the right intermediate pulmonary artery. TE technique using autologous cells was indicated. The application of this procedure was approved by the ethical committee in Tokyo Women's Medical University. The patient's parents were thoroughly informed and signed a consent form. Approximately 2 cm of the peripheral vein was explanted under sterile conditions. The tissue was minced, placed in tissue culture dishes and cultured at 37 degrees C, 100% humidity and a 5% CO2 atmosphere for almost a month. The number of cells substantially increased to reach 12 millions for almost a month. The culture medium was changed every 3 days. The polymer tube that served as a scaffold for cells was composed of the copolymer of PCL-PLA (50:50) with reinforcement by woven PGA. The polymer conduit, 10 mm in diameter, 20 mm in length and 1 mm in thickness, was designated to biodegradate within 8 weeks. The number of seeded cells was approximately a million/cm2. The graft transplantation was performed 10 days after seeding cells. The occlusive right intermediate pulmonary artery was reconstructed with the TE vessel graft under extracorporeal circulation with a pump-oxygenator. The patient followed a satisfactory postoperative course. The postoperative angiography demonstrated that the graft was not constricted and dilated but that it preserved good patency. Long-term follow-up are necessary. We plan to continue to use the TE technique using autologous cells in the low pressure system like venous or pulmonary circulation. Because our results even in early experimental phase were valuable and promising, we believe that the TE approach may play an important role in the near future as an another alternative, together with transplantation and artificial organ, especially in the field of cardiovascular surgery that mostly needs replants.
Collapse
Affiliation(s)
- N Hibino
- Department of Pediatric Cardiovascular Surgery, Heart Institute of Japan, Tokyo Women's Medical University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kawasaki H, Isoyama K, Eguchi M, Hibi S, Kinukawa N, Kosaka Y, Oda T, Oda M, Nishimura S, Imaizumi M, Okamura T, Hongo T, Okawa H, Mizutani S, Hayashi Y, Tsukimoto I, Kamada N, Ishii E. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood 2001; 98:3589-94. [PMID: 11739161 DOI: 10.1182/blood.v98.13.3589] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This study analyzed data on 35 infants with acute myeloid leukemia (AML) who were treated with intensive chemotherapy between 1995 and 1998 in Japan. The incidence of boys, younger age (< 6 months old), and hyperleukocytosis at onset was high in patients with the M4/M5 subtype (n = 23) in the French-American-British classification, compared with the non-M4/M5 subtype (n = 12). Thirteen (56%) and 16 (70%) patients with the M4/M5 subtype also showed 11q23 translocations and MLL gene rearrangements, respectively, whereas only one patient with the non-M4/M5 subtype had this rearrangement. All 35 patients were treated with the ANLL91 protocol consisting of etoposide, high-dose cytarabine, and anthracyclines. Overall survival and the event-free survival (EFS) rates at 3 years of all patients were 76% (95% confidence interval [CI], 61.3%-90.7%) and 72% (95% CI, 56.4%-87.9%), respectively. EFS showed no significant difference between 2 subgroups divided by age, gender, presence of the MLL gene rearrangements, and white blood cell count at onset; EFS in patients with the M4/M5 subtype tended to be better than those with the non-M4/M5 subtype. Although all 6 patients who underwent allogeneic stem cell transplantation (SCT) have been in complete remission, no benefit of SCT was confirmed. These findings suggest that the intensive chemotherapy with the ANLL91 protocol might have been responsible for the observed good outcome of infant AML, even without SCT. The presence of the MLL gene rearrangements or the age at onset had no impact on the outcome of infant AML.
Collapse
MESH Headings
- Aclarubicin/administration & dosage
- Antibiotics, Antineoplastic/administration & dosage
- Antibiotics, Antineoplastic/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Chromosomes, Human, Pair 11
- Cytarabine/administration & dosage
- Cytarabine/adverse effects
- DNA-Binding Proteins/genetics
- Disease-Free Survival
- Doxorubicin/administration & dosage
- Doxorubicin/analogs & derivatives
- Etoposide/administration & dosage
- Etoposide/adverse effects
- Female
- Hematopoietic Stem Cell Transplantation
- Histone-Lysine N-Methyltransferase
- Humans
- Immunophenotyping
- Infant
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/mortality
- Male
- Mitoxantrone/administration & dosage
- Myeloid-Lymphoid Leukemia Protein
- Prognosis
- Proto-Oncogenes
- Remission Induction
- Survival Rate
- Transcription Factors
- Translocation, Genetic
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- H Kawasaki
- Department of Pediatrics, Mie University, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|